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Summary 
 
Schistosomiasis is a chronic helminthic disease caused by fluke worms of the genus 
Schistosoma spp. The disease belongs to the so-called neglected tropical diseases (NTDs), 
a group of poverty-promoting chronic infectious diseases, which primarily occur in rural areas 
and poor urban areas of low-income and middle-income countries. Schistosomiasis is a 
major public health problem and endemic in approximately 78 countries of the world, but 
mainly in sub-Saharan Africa. It has been estimated that more than 207 million people 
worldwide are infected with schistosomiasis and 779 million people are at risk of contracting 
the disease. The annual mortality rate due to schistosomiasis in sub-Saharan Africa might be 
as high as 280,000.  
Overall, there are five schistosome species parasitizing humans, with  
Schistosoma haematobium (Sub-Saharan Africa, Middle East and some islands in the Indian 
Ocean), S. mansoni (Sub-Saharan Africa, parts of South America and some Caribbean 
islands) and S. japonicum (China, the Philippines and Indonesia) being the three main 
species with the widest geographical distribution. The disease is transmitted by contact with 
infested fresh water, containing the infectious stage of the parasites, the cercariae, which 
were released by infected aquatic snails and penetrate human skin. During penetration 
cercariae develop to larval stages, which enter the blood and develop into adult worms. 
Female schistosomes begin laying eggs, which either trapped in the tissues of the infected 
host or are excreted with the faeces or the urine. Chronic pathology and morbidity is not due 
to the adult worms itself, but due to inflammatory and granulomatous reactions provoked by 
the parasite eggs. For example, S. haematobium affect the bladder and the vesical and 
urethral walls and causes e.g. haematuria, ulcera and fibrosis (urinary schistosomiasis),  
S. mansoni affect the large bowel, the liver and the mesenteric veins and causes e.g. 
abdominal pain, ulcera and fibrosis (intestinal schistosomiasis). 
The WHO recommended strategy for control of schistosomiasis is morbidity control through 
regular treatment with praziquantel. Praziquantel is active against the adult stages of all five 
human schistosome species, however, it has only little or no effect on eggs and immature 
worms. Hence re-treatment is necessary to kill those parasites that have since matured. 
Overall, treatment is regarded as safe and generally well-tolerated. However, to date 
praziquantel is the only drug available for treatment and control of schistosomiasis. The 
dependence on only one drug for such an important helminthic infection and the massive use 
of praziquantel in mass drug administration programs is a considerable risk factor for the 
development of praziquantel resistant schistosome strains. In fact, resistance was already 
demonstrated in the laboratory and in some field studies. Furthermore, to date no vaccines 
Summary            vi 
 
 
against schistosomiasis are available. Therefore there is a need to develop new drugs 
against schistosomiasis. 
Recently the antimalarial drug mefloquine was found to have interesting antischistosomal 
activities in vitro and in the mouse model. For example, single oral doses of 200 or  
400 mg/kg mefloquine administered to mice infected with juvenile and adult stages of  
S. mansoni and S. japonicum resulted in high or complete total and female worm burden 
reduction. Treatment with a lower dose (150 mg/kg) revealed significantly reduced egg 
production in S. mansoni-infected mice. Furthermore, a clinical trial conducted with school 
children in Côte d´Ivoire showed that a mefloquine/artesunate combination cured 11 out of 
18 children infected with S. haematobium. 
 
Based on these findings, the aim of my PhD thesis was to further assess the newly 
discovered antischistosomal properties of the antimalarial drug mefloquine and to get a first 
insight into the mode of action and the pharmacodynamics of mefloquine in schistosomes. 
Therefore different in vitro and in vivo studies, including drug target discovery studies, were 
conducted with S. mansoni.  
 
By assessing the time-dependent drug effect of mefloquine on schistosomes we showed that 
mefloquine has a rapid onset of action on newly transformed schistosomula (NTS; artificially 
produced, non hematophagous) and a slightly slower onset of action on adult worms 
(recovered from infected mice) in vitro: 10 µg/ml killed adult worms within 24 h of incubation 
(LC50= 1.9 µg/mL). In the presence of hemin drug activities against adult S. mansoni were 
enhanced. In vivo already 72 h post treatment more than 90% of schistosomes were shifted 
to the liver, a criterion for drug activity, which shows how quick after drug treatment worms 
are forced to migrate from the mesenteric veins to the liver (ED50= 62 mg/kg). With scanning 
electron microscopy (SEM) studies, a common technique to document the efficacy of 
antischistosomal drugs on the parasites tegument, we confirmed our previous observations 
and the differences in the onset of action between in vitro and in vivo studies: SEM revealed 
extensive tegumental damages including blebbing, shrinking and sloughing on the tegument 
of NTS and adult worms, in particular following in vitro incubation and on the tegument of 
female worms.  
Furthermore, we showed conducting a small structure-activity relationship study that the 
optical isomers and the racemic forms of the chiral drug mefloquine have only moderate 
stereoselectivity, in particular in vivo, since prominent activities were observed with all 
derivates in the S. mansoni mouse model. 
To evaluate the potential of a mefloquine/praziquantel drug combination against S. mansoni 
we conducted combination studies and achieved encouraging results, since synergistic 
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effects in vitro and in the S. mansoni mouse model were seen, when both drugs were given 
simultaneously or when praziquantel treatment followed mefloquine. The latter administration 
regime achieved the best results and only moderate worm burden reductions were achieved 
when praziquantel was administered prior to mefloquine.  
Finally, to get a better knowledge about the mechanism of action of mefloquine in 
schistosomes we launched drug target discovery studies using affinity chromatography. We 
identified enolase, a glycolytic enzyme, as a major mefloquine- binding protein in S. mansoni 
schistosomula. We demonstrated that mefloquine interacts with glycolysis in schistosomula. 
To strengthen the field of antischistosomal drug discovery we assessed a new 
technique, isothermal microcalorimetry (IMC), to examine in vitro drug effects against 
S. mansoni. To date, the “gold standard” is microscopic reading, which is easy to 
handle and accomplishable in every laboratory, but difficult to standardize and 
subjective. We examined in vitro drug activities of three antischistosomal drugs and 
mefloquine against S. mansoni and compared t h e  r e s u l t s  to microscopic 
readouts. Both methods showed a good correlation, however, IMC identified drug 
effects that were not visible by microscopic evaluation and precisely determined the 
onset of action of the test drugs. Furthermore, we compared drug effects on NTS and 
adult schistosomes, because NTS are increasingly used in antischistosomal drug 
screening assays.  
 
In conclusion, my work has confirmed that mefloquine possesses excellent antischistosomal 
properties and that the drug might be an interesting partner drug in combination 
chemotherapy. 
We demonstrated that IMC is a useful tool for antischistosomal drug discovery and should 
therefore be assessed also for studying drug effects against other helminths. In addition, our 
data support the use of NTS in in vitro antischistosomal drug assays, since we observed 
similar drug sensitivities on both stages. 
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Zusammenfassung 
Schistosomiasis (oder auch Bilharziose) ist eine chronische Wurmerkrankung, verursacht 
durch Saugwürmer (Trematoda) der Gattung Schistosoma spp. Sie gehört zu den 
sogenannten vernachlässigten Tropenkrankheiten, einer Gruppe von chronischen 
Infektionskrankheiten, die vor allem in armen Gebieten von Ländern mit mittlerem oder 
niedrigem Einkommen auftreten. Die Bilharziose ist endemisch in rund 78 Ländern der Welt, 
vor allem aber kommt sie in Afrika südlich der Sahara (Sub-Sahara) vor. Dort ist sie ein 
grosses Problem der allgemeinen Volksgesundheit. Es wird geschätzt, dass mehr als  
207 Millionen Menschen weltweit mit Bilharziose infiziert und weitere 779 Millionen 
Menschen gefährdet sind. Die jährliche Todesrate aufgrund von Bilharziose wird allein im 
Endemiegebiet südlich der Sahara auf ungefähr 280.000 geschätzt. 
Insgesamt gibt es fünf Arten von Schistosomen (Pärchenegel), die den Menschen als 
Parasiten befallen. Die drei wichtigsten (mit ihrer jeweiligen geographischen Verteilung) sind  
Schistosoma haematobium (Sub-Sahara, Naher Osten und einige Inseln im Indischen 
Ozean), S. mansoni (Sub-Sahara, Teile von Südamerika und einige karibische Inseln) und  
S. japonicum (China, die Philippinen und Indonesien). Die Krankheit wird durch Kontakt mit 
kontaminiertem Wasser übertragen, welches das infektiöse Entwicklungsstadium, die 
Zerkarien, enthält. Diese werden von infizierten Wasserschnecken (als Zwischenwirt) 
ausgeschieden und infizieren den Menschen durch Penetration der Haut. Dabei verlieren die 
Zerkarien ihren Ruderschwanz und entwickeln sich zu Schistosomula (Larvenstadium, junge 
Schistosomen), welche dann über die Lymph- und Blutgefässe in die Pfortader und die 
intrahepatischen Gefässverzweigungen der Leber wandern, wobei sie sich zu adulten 
Würmern entwickeln. Dort vereinigen sich die Männchen und Weibchen zu Paaren, welche 
in die Mesenterial- und Darmvenen (S. mansoni) bzw. das Venengeflecht der Blase und des 
Enddarms (S. haematobium) migrieren. Die weiblichen Schistosomen beginnen Eier zu 
legen, welche sich entweder in den entsprechenden Geweben des infizierten Wirtes 
einnisten oder mit dem Kot oder Urin ausgeschieden werden. Krankheitssymptome werden 
nicht durch die Würmer selbst ausgelöst, sondern durch die eingenisteten Eier, welche 
entzündliche und granulomatöse Gewebsreaktionen auslösen. S. haematobium zum Beispiel 
verursacht unter anderem Hämaturie, Ulcera und Fibrosen an Blasen- und Harnleiterwänden 
(Harn-Bilharziose) und S. mansoni befällt Dickdarm, Pfortader und die Mesenterialvenen und 
verursacht Abdominalschmerzen, Geschwüre und Leberfibrosen (Darm-Bilharziose). 
Die WHO-Strategie zur Bekämpfung der Bilharziose besteht in der regelmässigen 
Behandlung mit Praziquantel. Praziquantel ist gegen alle adulten Stadien der fünf 
menschenpathogenen Schistosomaarten wirksam, wobei es nur geringe oder gar keine 
Zusammenfassung           ix 
 
 
Wirkung auf Eier und junge Würmer hat. Daher ist eine erneute Behandlung, nach 
Heranreifen dieser Stadien zu adulten Schistosomen, notwendig, um diese endgültig und 
vollständig abzutöten. Die Behandlung wird insgesamt als sicher und allgemein gut 
verträglich angesehen. Allerdings ist Praziquantel bisher das einzige zur Verfügung stehende 
Medikament zur Behandlung und Eindämmung der Bilharziose. Die Tatsache, dass nur ein 
einziges Medikament gegen eine so schwere und weit verbreitete Wurminfektion zur 
Verfügung steht und dass durch den dadurch bedingten massiven Einsatz von Praziquantel 
ein erhebliches Risiko für die Entstehung von Resistenzen besteht, veranlasst zu grosser 
Sorge. Tatsächlich wurden bereits im Labor und in einigen Feldversuchen Praziquantel 
resistente Schistosomastämme nachgewiesen. Darüber hinaus gibt es noch keine Impfstoffe 
gegen die Bilharziose. Aus diesen Gründen besteht ein grosser Bedarf, neue Medikamente 
gegen Schistosomaisis zu entwickeln bzw. bereits vorhandene auf deren mögliche 
Wirksamkeit zu prüfen.  
Kürzlich wurde gezeigt, dass das Antimalariamittel Mefloquin sowohl in vitro als auch im 
Mausmodell interessante antischistosomale Wirkungen hat. Zum Beispiel führten orale 
Einzeldosen von 200 oder 400 mg/kg Körpergewicht bei Mäusen, welche mit jugen und 
adulten Stadien von S. mansoni und S. japonicum infiziert waren, zu einer starken 
Verringerung der gesamten Wurmlast oder sogar zur vollständigen Eliminierung der 
weiblichen Würmer. Die Behandlung mit einer niedrigeren Dosis (150 mg/kg Körpergewicht) 
bewirkte eine deutlich reduzierte Eierproduktion in S. mansoni-infizierten Mäusen. Eine 
klinische Studie an der Elfenbeinküste zeigte, dass 11 von 18 mit S. haematobium infizierten 
Schulkindern mit einer Kombination von Mefloquin und Artesunat, einem weiteren 
Antimalariamittel, geheilt werden konnten. 
 
Basierend auf diesen Ergebnissen war das Ziel meiner Dissertation, die neu entdeckten 
antischistosomalen Eigenschaften des Antimalariamittels Mefloquin weiter zu untersuchen 
und somit einen Einblick in die Wirkungsweise von Mefloquin in Schistosomen zu 
bekommen. Dazu haben wir verschiedene in vitro und in vivo Studien, einschliesslich Target 
Discovery Studien mit S. mansoni, durchgeführt. 
 
Wir konnten zeigen, dass Mefloquin in vitro einen sehr schnellen Wirkungseintritt bei 
Schistosomula hat (NTS; frisch im Labor aus Zerkarien hegestellt, nicht haematophag) und 
einen etwas langsameren auf adulte Würmer (durch Sektion aus infizierten Mäusen 
gewonnen), wobei eine Konzentration von 10 µg/ml adulte Schistosomen innerhalb von  
24 Std. Inkubationsszeit töteten (LC50= 1,9 µg/ml). In Anwesenheit von Hämin wurde die 
Wirksamkeit gegen adulte Formen noch verbessert. In vivo waren 72 Std. nach der 
Behandlung mehr als 90% der Schistosomen aus den Mesenterialvenen in die Leber 
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gewandert (ED50= 62 mg/kg). Dieser Leber-Shift ist ein Kriterium zur Beurteilung der 
Wirksamkeit eines antischistosomalen Wirkstoffes. Mit der Rasterelektronenmikroskopie 
(REM), einer Technik um die Wirksamkeit von Arzneistoffen an der Wurmoberfläche 
(Tegument) zu untersuchen, bestätigten wir unsere bisherigen Beobachtungen und die 
Unterschiede im Wirkungseintritt zwischen in vitro und in vivo Studien. Wir konnten zeigen, 
dass Mefloquin sowohl bei NTS, als auch bei adulten S. mansoni, eine starke Zerstörung des 
Tegumentes mit Blasen- und Faltenbildung und sogar partiellem Ablösen der oberen Schicht 
hervorrief. Dies war insbesondere in vitro und bei den Weibchen zu beobachten. 
In einer Studie zur Struktur-Aktivitäts-Beziehung zeigten wir, dass der chirale Wirkstoff 
Mefloquin nur eine mässige Stereoselektivität besitzt, weil im Mausmodell sowohl mit den 
einzelnen optischen Isomeren als auch mit beiden racemischen Formen sehr gute 
Wirkungen gegen S.mansoni beobachtet werden konnten.  
Um das Potential einer Mefloquin/Praziquantel-Wirkstoffkombination gegen S. mansoni zu 
prüfen, führten wir Kombinationsstudien durch und erzielten ermutigende Ergebnisse. 
Sowohl in vitro als auch im S. mansoni -Mausmodell sahen wir synergistische Effekte, wenn 
beide Medikamente gleichzeitig gegeben wurden oder wenn Praziquantel der 
Mefloquinbehandlung folgte. Wenn umgekehrt Mefloquin zuerst verabreicht wurde, zeigte 
sich nur ein mässiger Effekt. 
Um den Wirkmechanismus von Mefloquin in Schistosomen besser zu verstehen und 
mögliche Targetproteine zu identifizieren, führten wir Target Discovery Studien mit Hilfe der 
Affinitätschromatographie durch. In einem ersten Schritt, identifizierten wir Enolase, ein 
Enzym der Glykolyse, als ein wichtiges Mefloquin bindendes Protein in S. mansoni 
Schistosomula. In einem zweiten Schritt konnten wir zeigen, dass Mefloquin in die Glykolyse 
der Schistosomula eingreift und so wahrscheinlich den Tod der Würmer mit verursacht. 
Um die antischistosomale Wirkstoffforschung voranzutreiben, untersuchten wir die 
Einsatzfähigkeit einer neuen Methode, der isothermalen Mikrokalorimetrie (IMC), zum in vitro 
Screening von Arzneimittelwirkungen gegen S.mansoni. 
Bis heute ist die mikroskopische Beobachtung der "Goldstandard" in dieser Art der 
Wirkstoffforschung. Sie ist einfach zu handhaben und in jedem Labor durchführbar, 
allerdings schwierig zu standardisieren und immer von der subjektiven Bewertung des 
Beobachters abhängig. Wir untersuchten in vitro die Wirkungen von drei bekannten 
antischistosomalen Stoffen (Praziquantel, Oxamniquin und Artesunat) und Mefloquin gegen 
S. mansoni mit IMC und verglichen die Ergebnisse mit denen der mikroskopischen 
Untersuchungen. Beide Methoden zeigten eine gute Korrelation bei den Ergebnissen, jedoch 
lassen sich mit IMC Wirkungen nachweisen, die mit der mikroskopischen Auswertung 
entweder gar nicht oder erst viel später nachweisbar waren. Des Weiteren liess sich der 
Zeitpunkt des Wirkeintritts genauer feststellen. 
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Ausserdem verglichen wir Arzneimittelwirkungen auf NTS und adulte Schistosomen, weil 
NTS zunehmend in Screening-Assays zur Suche nach antischistosomalen Wirkstoffen 
verwendet werden. 
 
Insgesamt konnte ich mit meiner Arbeit zeigen, dass Mefloquin ausgezeichnete 
antischistosomale Eigenschaften besitzt und ein interessanter Wirkstoff in einer 
Kombinations- Chemotherapie der Bilharziose sein könnte. Ausserdem haben wir gezeigt, 
dass IMC eine nützliche Methode in der antischistosomalen Wirkstoffforschung ist und daher 
auch bei der Untersuchung von weiteren Wirkstoffen gegen andere Wurmarten eingesetzt 
werden könnte. Zusätzlich unterstützen unsere Untersuchungsergebnisse die Verwendung 
von NTS in in vitro Assays in der antischistosomalen Wirkstoffforschung, weil sowohl NTS 
als auch adulte Schistosomen ähnliche Empfindlichkeiten gegen Testsubstanzen zeigten 
und erstere einfacher zu gewinnen sind. 
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1.  Introduction 
Schistosomiasis is a chronic helminthic disease and belongs to the so-called neglected 
tropical diseases (NTDs). The causative agents are parasitic fluke worms of the genus 
Schistosoma spp. In this introduction first, a brief overview of the umbrella term NTDs is 
given (Section 1.1). In Section 1.2 a summary of the disease schistosomiasis, including the 
taxonomy, the morphology, the life cycle, the global burden and the pathology is described. 
The current global strategy for schistosomiasis treatment and control is outlined in Section 
1.3. Section 1.4 highlights research needs and Section 1.5 provides a background on the 
antischistosomal properties of mefloquine. 
 
1.1. Neglected Tropical Diseases (NTDs) 
Overall, there is no standard global definition for the term neglected tropical diseases 
(NTDs). The journal PLoS Neglected Tropical Diseases defines it as a group of poverty-
promoting chronic infectious diseases, which primarily occur in rural areas and poor urban 
areas of low-income and middle-income countries. They are poverty-promoting because of 
their impact on child health and development, pregnancy, and worker productivity, as well as 
their stigmatizing features (http://www.plosntds.org/static/scope.action). Many parasitic and 
bacterial infections are included in the list of NTDs, within approximately 37 major diseases. 
One of these diseases is schistosomiasis, which is a major public health problem in sub-
Saharan Africa.  
Collectively, the NTDs represent one of the most serious burden to public health among the 
most deprived communities (Liese et al., 2010) estimated global burden due to the NTDs is > 
50 million disability-adjusted life years (DALYs), which represent the fourth most important 
group of communicable diseases worldwide, behind lower respiratory infections, HIV/AIDS 
and diarrhoeal diseases (Hotez et al., 2006a). However, in the global health policy NTDs 
have been largely ignored; for example, only 0.6% of funding of official development 
assistance was spent on NTDs control projects during the last couple of years (Liese and 
Schubert, 2009).  
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1.2. Schistosomiasis 
Taxonomy  
Schistosomiasis is a chronic parasitic 
inflammatory disease caused by fluke 
worms of the genus Schistosoma. In 
Figure 1 the basic taxonomy of these 
parasites is shown. Overall, there are five 
schistosome species parasitizing humans, 
with Schistosoma haematobium,  
S. mansoni and S. japonicum being the 
three main species with the widest 
geographical distribution (Utzinger and 
Keiser, 2004, Gryseels et al., 2006)     Figure 1. Taxonomy of Schistosoma spp. 
 
Morphology 
Schistosomes have separate sexes and live as permanently embraced couples, with the 
thinner female in a slit in the male’s body, in mesenteric veins (S. intercalatum, S. japonicum, 
S. mansoni and S. mekongi) or the vesical plexus and veins that drain the urether 
(S. haematobium). The name schistosoma is derived from Greek and is based on the special 
morphology of the male’s body: schistos means “split”, soma means “body”. 
Overall, worms vary in morphology, egg 
shape and size according to species and 
sex. For example, worm size range 
between 7-20 x 0.25-1 mm. However, one 
morphological characteristic, which all 
schistosomes (and digeneans in general) 
have in common, is the dorso-ventral 
flattening, bilaterally symmetrical body. 
Additionally, all species have an oral and 
ventral sucker and no circulatory system. 
An overview of the morphology of 
schistosomes is shown in Figure 2. 
 
 
Figure 2. Schematic illustration of a male and female 
adult S. mansoni and a S. mansoni egg 
(source :http://course1.winona.edu/kbates/Parasitolo
gy/Images/Schistosomemorph.png) 
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Life cycle 
Schistosomiasis is transmitted through contact with infested fresh water, containing the 
infectious stage of the parasites, the cercariae, which were released by aquatic snails 
carrying the parasite. Playing activities such as swimming and bathing, occupational 
activities like fishing and irrigated rice farming as well as daily household activities can put 
people at risk of acquiring schistosomiasis (Keiser and Utzinger, 2011) 
(http://globalnetwork.org/files/press_releases/schistosomiasis.pdf). For a better 
understanding, the life cycle of schistosomiasis is illustrated in Figure 3. Briefly, people 
become infected when they come in contact with water containing cercariae which penetrate 
human skin. In this process cercariae lose their tails, develop to larval stages 
(schistosomula) and finally enter the blood vessels via the lymphatics. Schistosomula 
develop into adult worms, mate and female schistosomes begin laying eggs. The number of 
eggs passed daily into the venules depend upon the species of worm, which ranges between 
300 (S. mansoni) to 3500 (S. japonicum) (Neva and Brown). Some of the eggs are trapped in 
the tissues of the infected host, and some of the eggs are excreted with the faeces  
(S. intercalatum, S. japonicum, S. mansoni and S. mekongi) or the urine (S. haematobium 
and S. japonicum). Once eggs reach a freshwater body, they develop, release miracidiae, 
which then search for the intermediate host, the aquatic snails. Within the snail, asexual 
multiplication takes place and resulting cercariae are released from infected snails into the 
water. 
Figure 3. S. mansoni A) schistosomes in culture media, freshly removed from 
infected mice B) Light microscope picture of a female and male worm C) SEM 
picture of a S. mansoni couple 
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Figure 4. Life cycle of schistosomiasis (modified, according to CDC, Centers for disease control and 
prevention, http://www.cdc.gov/parasites/schistosomiasis/biology.html) 
 
Global burden of schistosomiasis 
Schistosomiasis is a major public health problem and endemic in approximately 78 countries 
of the world. S. haematobium, S. mansoni and S. japonicum have the widest geographical 
distributions and are of particular public health and economic significance  
(Steinmann et al., 2006). The global distribution of the disease is shown in Figure 4. It has 
been estimated that more than 207 million people worldwide are infected with 
schistosomiasis and 779 million people are at risk of contracting the disease  
(Steinmann et al., 2006). The highest infection prevalence is found in school-aged children 
(SAC) and young adults (Neva and Brown). The annual mortality rate due to schistosomiasis 
in sub-Saharan Africa might be as high as 280,000 (van der Werf et al., 2003). Estimates of 
the global burden of schistosomiasis range from 1.7 to 4.5 million disability adjusted life 
years (DALYs) (Hotez and Fenwick, 2009) through direct pathologies associated with the 
disease and consequences including impaired child growth, malnutrition and anaemia. But 
since the latter figure does not consider chronic disability (Hotez et al., 2006b), one can 
speculate that the number of DALYs is likely to be underestimated. Another calculation 
comes to the conclusion that estimates for schistosomiasis are at 3-70 million DALYs  
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(King and Dangerfield-Cha, 2008). Overall, the DALYs represent a summary measure of 
both mortality and disability to quantify and compare the health of populations 
(Mathers et al., 2007). 
 
Figure 5. Global distribution of schistosomiasis 2009 (source: WHO (WHO, 2011)) 
 
Pathology 
Pathology of schistosomiasis can be divided into two stages, acute and clinical pathology. 
Acute pathology develops following cercarial penetration of human skin and the subsequent 
maturation to adult worms. The clinical manifestations produced by the three main 
schistosome species are similar: due to penetration of cercariae a temporary urticarial rash 
or cercarial dermatitis might occur. Acute schistosomiasis (Katayama fever) is a systemic 
hypersensitivity reaction caused by the migrating schistosomula, which might result in fever, 
fatigue, myalgia and later abdominal symptoms (Gryseels et al., 2006, Neva and Brown). 
The second stage is the chronic pathology and morbidity, which depend upon the parasite 
species and is due to the parasite eggs. Systemic signs might occur in the period of active 
oviposition and egg excretion by the schistosomes. Further established and chronic 
infections develop when inflammatory and granulomatous reactions due to proteolytic 
enzymes secreted by the eggs appear (Neva and Brown). Clinical manifestations caused by 
the three main schistosome species and their global distribution are summarized table 1. 
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Table1. Clinical manifestations caused by the three main schistosome species and their global 
distribution (source: (Gryseels et al., 2006)) 
 
1.3. Global strategy for schistosomiasis treatment and 
control  
The WHO recommended intervention strategy for control of schistosomiasis is morbidity 
control through regular and targeted large scale preventive chemotherapy (WHO, 2006). 
People living in endemic areas or people defined as being at high risk are therefore treated 
without a previous individual diagnosis. Population considered to be at high risk are one the 
one hand school-age children and one the other hand adults from special groups, such as 
pregnant and lactating women and people who have regular contact with infested water, 
such as fishermen, farmers or women doing their daily laundry. The frequency of the 
treatment varies according to the risk of schistosomiasis. In high-risk communities treatment 
should take place once a year, in moderate-risk communities once every 2 years and in low-
risk communities children will be treated twice during primary school (WHO, 2006) 
Chemotherapy is carried out with the drug praziquantel. The WHO recommended use is a 
single 40 mg/kg oral dose of praziquantel (marketed as 600 mg tablets). When high initial 
egg counts are recorded and therefore a risk for rapid re-infection exists, higher doses of 60 
mg/kg (or even higher, maybe dose splitting) are recommended (WHO, 2006).  
Praziquantel has a broad spectrum of activity, because it is active against the adult stages of 
all five human schistosome species. Additionally, praziquantel is efficacious against soil-
transmitted helminthiasis (some liver flukes, e.g. Clonorchis sinensis and 
Opisthorchis viverrini and lung flukes, e.g. Paragonimus westermani) (Cioli and Pica-
Mattoccia, 2003). The drug acts within 1 h of ingestion by paralysing the worms and 
 Distribution Affected organs Symptoms 
S. haematobium 
Sub-Saharan Africa, 
Middle East, some islands 
in the Indian Ocean 
Bladder, kidneys, 
vesical and urethral 
walls 
Haematuria, ulcera, fibrosis, calcification 
,bladder stones, carcinoma, bladder 
cancer, hydrourether, nephrosis, kidney 
failure,  
S. mansoni 
Sub-Saharan Africa, parts 
of South America, some 
Caribbean islands 
Large bowel, rectum, 
liver, portal vein, 
mesenteric veins 
Abdominal pain, discomfort, bloody 
diarrhoea, ulcera, hepatomegaly, 
fibrosis, portal hypertension, GI-varices, 
ascites 
S. japonicum China, the Philippines, 
and Indonesia 
Circulation 
Sudden and massive bleeding, 
abdominal pain, abscesses, bloody 
diarrhoea, ulcera, hepatomegaly, 
fibrosis, portal hypertension 
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damaging the tegument (Andrews, 1985). However, the drug has only little or no effect on 
eggs and immature worms. Hence re-treatment is necessary to kill those parasites that have 
since matured. The preferred time for follow up treatment is 4-6 weeks  
(Gryseels et al., 2006). Overall, treatment is regarded as safe and generally well-tolerated, 
and can be used in pregnant woman and in young children (note that no safety information is 
available for children under four years of age) (WHO, 2002). Only light and temporary side 
effects, including weakness, abdominal pain, dizziness, headache and nausea might occur 
(reported occurrence  10%) (Utzinger and Keiser, 2004). However, in heavy infections 
acute colic with bloody diarrhoea provoked by massive worm shifts and antigen release can 
occur (Stelma et al., 1995).  
However, to date, praziquantel is the only drug available for treatment and control of 
schistosomiasis (Doenhoff et al., 2009, Utzinger and Keiser, 2004). Praziquantel originates 
from a spate of isoquinoline-pyrazino derivatives, which were synthesised as potential 
tranquilizer in the early 1970s (Bayer Schering Pharma and Merck KGaA, Germany)  
(Hotez et al., 2010). Further laboratory investigations with praziquantel in 1976/1977 showed 
its antihelminthic activity and the first clinical trials in humans were carried out in 1978/1979 
(Utzinger and Keiser, 2004). There are presently no real alternatives to praziquantel, since 
metrifonate (against S. haematobium) has been withdrawn from the market and oxamniquine 
is only active against S. mansoni and difficult to obtain (Doenhoff et al., 2002, Utzinger and 
Keiser, 2004).  
 
1.4. The need for novel antischistosomal drugs 
Although praziquantel is a very efficacious and safe antischistosomal drug (as described in 
section 1.3), there are five reasons justifying the need to discover and develop new drugs 
against schistosomiasis (Caffrey, 2007, Ribeiro-dos-Santos et al., 2006): First, the global 
strategy for schistosomiasis control is based on morbidity control, but to date only one single 
drug, namely praziquantel, is deployable for antischistosomal chemotherapy (Keiser and 
Utzinger, 2007). The dependence on one drug for an important helminthic infection that 
affects approximately 207 million people in the poorest areas of the world is of great concern 
(Caffrey and Steverding, 2008). Second, the massive use of praziquantel in mass drug 
administration programs recommended by the World Health Organisation  
(Doenhoff et al., 2009) is a considerable risk factor for the development of resistant 
schistosome strains to praziquantel. In fact, resistance to praziquantel in S. mansoni infected 
mice was already demonstrated in laboratory studies in 1994 (Doenhoff et al., 2002) 
(Melman et al., 2009). Furthermore, in field studies conducted in Senegal and Egypt and 
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published in 2001 and 2005, respectively, treatment failures potentially explainable through 
praziquantel-tolerant schistosomes strains were observed: In the first case, treatment of  
S. mansoni infected patients achieved low cure rates, ranging from 18-39%. In the second 
study, patients repeatedly treated with praziquantel continued excreting viable parasite eggs 
(Utzinger and Keiser, 2004). Third, there are currently no vaccines available to prevent an 
infection with schistosomiasis, even if some potential vaccine candidates were identified 
(recombinant rShGST-28, phase I and II of clinical trials) it will take a long time before these 
vaccines will be commercially available (Bergquist and Colley, 1998, Zhang et al, Capron et 
al., 2005 ). Fourth, due to the narrow spectrum of activity of praziquantel a second dose of 
praziquantel has to be administered after a short interval, to eliminate parasites that have 
since matured. Observed treatment failures could possibly also be explained by this. The last 
reason, which justifies the development of a new antischistosomal drug is, that once an 
alternative drug is found (especially with another mechanism of action), the new drug could 
not only be used alone, but also in combination with praziquantel. Combination 
chemotherapies are recognised to be a viable therapeutic strategy to delay the development 
of drug resistance, because different drug targets are affected, thus increasing the life time of 
each individual drug. Additionally, combination chemotherapy ideally exceeds the individual 
effect of each drug alone and is often better tolerated (Utzinger et al., 2003). 
1.5. The antischistosomal properties of the antimalarial mefloquine 
In 1973 the WHO listed a group of new experimental antimalarial compounds, which were to 
be further tested in order to develop a new drug against chloroquine-resistant malaria 
(Sweeney, 1981, Trenholme et al., 1975). All compounds were developed by the U.S. Army 
at the Walter Reed Army Institute of Research. Out of the compounds assessed, mefloquine, 
a 4-quinoline-methanol and a synthetic analogue of quinine, was efficacious against drug-
susceptible and multi drug resistant P. falciparum (Sweeney, 1981, Trenholme et al., 1975). 
In 1989 mefloquine was approved by the American Food and Drug Administration (FDA) for 
the prophylaxis and treatment of malaria (www.FDA.gov). Mefloquine is effective against all 
forms of malaria and is currently used either in combination with artesunate (as one 
possibility of the WHO recommended artemisinin- based combination therapy (ACT)) or as 
monotherapy for the treatment of malaria (WHO, 2010).  
Now, around 20 years after its discovery, mefloquine has received renewed attention: In 
recently conducted in vivo studies in mice mefloquine showed interesting antischistosomal 
activities (Keiser et al., 2009). Single oral doses of 200 or 400 mg/kg of the antimalarial 
administered to mice infected with adult stages of S. mansoni and S. japonicum resulted in 
high or complete total and female worm burden reduction of 72.3-100%. High worm burden 
reductions were also achieved in mice infected with the juvenile form of both parasites 
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species (Keiser et al., 2009). Van Nassauw and colleagues showed that a treatment with a 
lower dose of mefloquine (150 mg/kg) revealed a significantly reduced egg production in  
S. mansoni-infected mice (Van Nassauw et al., 2008). In vitro studies with juvenile and adult 
S. japonicum and histopathological investigations of livers from S. japonicum infected mice 
confirmed the antischistosomal activities exhibit by mefloquine against both stages of  
S. japonicum (Xiao and Zhang, 2009, Xiao et al., 2009, Zhang et al., 2009) 
Another in vivo study carried out with mefloquine revealed, that even in athymic and 
immunocompetent S. mansoni infected mice mefloquine has antischistosomal activities. An 
oral dose of 200 mg/kg resulted in total and female worm burden reductions of 80.4-87.3% 
against juvenile and adult worms in a mutant mouse strain with T-cell deprived mice (Keiser 
et al., 2010b).  
To evaluate the effect of mefloquine against Schistosoma infections in humans a 
randomized, exploratory open-label trial was conducted in Cote d´Ivoire: the efficacy of 
mefloquine, artesunate and the combination mefloquine/artesunate (administered according 
to malaria treatment schemes) were investigated in S. haematobium infected school children 
(Keiser et al., 2010a). Mefloquine/artesunate combination chemotherapy reached high cure 
rates of 61% (11 out of 18 children) and egg-reduction rates of > 95% against  
S. haematobium infections. Praziquantel, the current treatment of choice, achieved cure and 
egg reduction rates of 88% and > 95%, respectively. 
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2. Study aim, objectives and approaches 
 
The overall aim of my Ph.D. thesis was to further assess the newly discovered 
antischistosomal properties of the antimalarial drug mefloquine and to get a first insight into 
the mode of action of mefloquine in schistosomes. This will be achieved on the one hand 
through drug efficacy and morphological studies with mefloquine and the isomeric and 
racemic forms of mefloquine, and on the other hand with combination chemotherapy studies. 
Additionally, drug target discovery by the means of affinity chromatography will be carried 
out. In addition, to strengthen the field of drug discovery, I assessed the use of isothermal 
microcalorimetry for antischistosomal drug screening by using schistosomula and adult 
worms. 
 
Objective 1 
To s tudy morphological effects and tegumental alterations induced by mefloquine 
on schistosomula and adult flukes of S. mansoni 
 
Approach: 
Dose-response relationships and temporal drug effects  w i l l  b e  s t u d i e d  in vitro and 
in vivo. To examine drug effects in greater detail, the tegumental surface of parasites will be 
examined by the means of scanning electron microscopy (SEM). SEM studies will be done 
in collaboration with the Centre for Microscopy at the University of Basel, Switzerland. 
In vitro studies: Schistosomula (1-7 day-old schistosomes, newly transformed 
schistosomula (NTS)) and adult S. mansoni (49- day old schistosomes) will be incubated 
with different concentrations of mefloquine (100-1 µg/ml). NTS will be artificially produced by 
mechanical transformation in the laboratory. NTS are model parasites, whose use in 
antischistosomal drug screening assays is in line with the requirements of the 3R protection 
principles to reduce, refine and replace animal experiments, since NTS are produced without 
the need of any mice. Worms will be assessed microscopically (at least every 24 h) up to 
four days. Drug effects will be assessed with an emphasis on changes in worm motor activity 
and morphological alterations. Afterwards worms will be prepared for SEM examinations and 
assessed. 
In vivo studies: Laboratory mice will be infected with S. mansoni cercariae. Once worms 
have matured, mice will be treated orally with mefloquine (400 mg/kg). 24, 48, 72 and 96 h 
post treatment schistosomes will be recovered from infected mice and distribution of worms 
in the mesenteric veins and the liver will be recorded. Afterwards worms will be analyzed by 
SEM. 
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Objective 2 
To compare the antischistosomal properties of the four mefloquine isomers and two 
racemates in vitro and in vivo 
 
Approach: 
To assess the antischistosomal properties of the four optical isomers and two racemates of 
the chiral drug mefloquine on S. mansoni NTS and adult S. mansoni in vitro and in vivo  
Additionally, we will assess, whether the antischistosomal efficacy of mefloquine depends on 
hemin. 
In vitro studies: The effect of the six different compounds on schistosomes will be analyzed 
microscopically and by the means of isothermal microcalorimetry (IMC). Schistosomes will 
be incubated in the presence and absence of hemin.  
In vivo studies: The effect of single oral doses of 200 mg/kg of the drugs will be assessed 
on adult S. mansoni harbored in mice. 
 
Objective 3 
To evaluate isothermal microcalorimetry (IMC) for antischistosomal drug screening 
 
Novel tools should facilitate the readout of in vitro antischistosomal drug screening. IMC is a 
highly sensitive and accurate tool to detect heat produced by microorganisms. We will 
examine whether IMC is applicable to analyze antischistosomal activities of test drugs.  
 
Approach: 
We will study in vitro drug effects of praziquantel, oxamniquine, artesunate and mefloquine 
on the metabolic activity and the motility of S. mansoni NTS and adult worms by using IMC. 
Microcalorimetric results will be compared to results obtained by microscopic readouts of 
viability, the standard method for compound screening against schistosomiasis.  
 
Objective 4 
To assess the applicability of NTS for antischistosomal drug screening assays 
 
Approach 
The same experimental setting as explained in Objective 3 will be used to assess the 
applicability of S. mansoni NTS for antischistosomal drug screening assays. Both, the 
schistosomular stages as well as the adult stages of S. mansoni will be incubated with the 
test drugs and phenotypes of parasites will be assessed microscopically and by 
microcalorimetric measurements. Results of drug effects on NTS and the adult worms will be 
compared. 
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Objective 5 
To investigate the antischistosomal properties of mefloquine/praziquantel 
combinations in vitro and in the mouse model 
 
Approach: 
Dose response relationships will be discovered following exposure of adult S. mansoni to 
mefloquine, praziquantel and fixed dose combinations of mefloquine/praziquantel in vitro.  
S. mansoni-infected mice will be treated orally with selected doses of single drugs and drug 
combinations 7 weeks post-infection. 
 
Objective 6 
To find a possible drug target of mefloquine in schistosomes 
 
Approach: 
In order to identify mefloquine binding proteins in extracts of S. mansoni schistosomula, 
affinity chromatography experiments will be performed using mefloquine-agarose. Since the 
mechanism of action and the molecular targets for mefloquine in schistosomes are not 
known and due to the fact that schistosomula are not blood feeders, this parasites stage 
allows identifying possible mefloquine targets besides heme degradation 
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8. Overall discussion and conclusions 
The overall aim of this Ph.D. thesis was to further assess the newly discovered 
antischistosomal properties of the antimalarial drug mefloquine (Keiser et al., 2009). The 
finding that mefloquine possess antischistosomal activities is the result of a successful 
applied “piggy back” strategy. This strategy is often used when two diseases share the same 
target and thus a chemical ‘starting point’ for subsequent investigations is provided  
(Nwaka and Hudson, 2006). In our case, Plasmodia spp. and Schistosoma spp both degrade 
hemoglobin and additionally, have a geographical overlap (Sangweme et al., 2010, Hotez et 
al., 2006). Therefore marketed antimalarials, which have hemoglobin as putative target, were 
assessed on their effect against schistosomes. Mefloquine was found to be a potential drug 
candidate for schistosomiasis with activities against all stages of S. mansoni and  
S. japonicum in vivo (Keiser et al., 2009). This drug discovery strategy is fast and cost-
effective, since for established drugs, clinical trials including toxicological studies have 
already been conducted and clinical experience exist (Dissous and Grevelding, 2011). 
 
Therefore different in vitro and in vivo studies were conducted with Schistosoma mansoni. 
We have performed in vitro studies using adult schistosomes (recovered from infected mice) 
and newly transformed schistosomula (NTS; artificially produced, non hematophagous) 
investigating drug effects on motility and morphology (light and electron microscopy) and on 
metabolism (microcalorimetry). Moreover, we have used the mouse model to study drug 
effects in vivo (Keiser, 2010). 
Findings should feed into a better understanding of the activity profile of mefloquine and the 
possible mechanism of action in schistosomes. An understanding of these parameters is 
crucial for the potential clinical utility of mefloquine in the treatment and control of 
schistosomiasis. In addition, the field of antischistosomal drug discovery was strengthened 
by development of a novel screening method.  
 
In the first part of the discussion I will summarize the key facts of my research. In the second 
part of the discussion, results obtained in drug efficacy and mode of action studies are 
reviewed and critically assessed. In the third part, findings of drug discovery and 
methodological issues of my studies are discussed. The fourth section comments on new 
treatment options. The fifth part provides implications and suggestions for further research 
and finally, in the last part of the discussion I will draw a conclusion. 
 
8.1. Research highlights 
The results described in detail in the previous chapters confirm the recently discovered 
antischistosomal properties of mefloquine in vitro and in vivo. Furthermore, they give an 
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insight into the spectrum of activity and the pharmacodynamics of mefloquine on S. mansoni. 
Below I summarize the key results: 
 
1. Mefloquine has a rapid onset of action on NTS and a slightly slower onset of action 
on adult worms in vitro (10 µg/ml killed adult schistosomes within 24 h of incubation, 
LC50=1.9 µg/mL).  
2. In vivo already 72 h post treatment with mefloquine more than 90% of schistosomes 
were shifted to the liver (ED50= 62 mg/kg), a criterion for drug activity, which shows 
how quick after drug treatment worms are forced to migrate from the mesenteric 
veins to the liver (Buttle and Khayyal, 1962). In S. japonicum infected mice worms 
shifted within 48 h post mefloquine treatment to the liver (Zhang et al., 2009). For 
comparison, praziquantel, the standard drug for treatment and control of 
schistosomiasis killed worms in vivo within 24 h. 
3. Activities against adult S. mansoni are enhanced in the presence of hemin.  
4. Scanning electron microscopy (SEM) studies revealed extensive disruption on the 
tegument of S. mansoni schistosomula and adult worms after mefloquine treatment, 
in particular following in vitro incubation and on the tegument of female worms. In 
contrast, praziquantel provokes more extensive tegumental damage to the male 
worms 
5. The four optical isomers and the two racemic forms of the chiral drug mefloquine 
showed only moderate stereoselectivity in their antischistosomal activity in vivo.  
6. Isothermal microcalorimetry (IMC) is a useful tool to study drug effects on 
schistosomes.  
7. Mefloquine interacts with the glycolytic enzyme enolase in S. mansoni schistosomula 
and thus with glycolysis.  
8. Mefloquine/praziquantel combinations reveal synergistic effects in vitro and in the  
 S. mansoni mouse model when both drugs are given simultaneously or when 
praziquantel treatment followed mefloquine.  
9. Our studies support the use of NTS in in vitro antischistosomal drug assays, since 
similar sensitivities on NTS and adult schistosomes were observed with test drugs. 
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8.2. Mefloquine: Antischistosomal properties and mode of action 
in S. mansoni 
 
Investigations on the temporal drug effect of mefloquine revealed a very fast onset of action 
on the schistosomular stage (NTS) and a slightly slower onset of action on adult 
schistosomes in vitro. However, 10 µg/ml mefloquine (~24 µM) killed adult worms within 24 h 
of incubation.  
In vivo 72 h after treatment more than 90% of schistosomes were shifted to the liver, which 
was also seen in the previous published in vivo study (Keiser et al., 2009). In S. japonicum 
infected mice, a slightly faster hepatic shift was observed after mefloquine treatment, since 
all worms were shifted to the liver within 48 h (Zhang et al., 2009). For comparison, 
praziquantel, the standard drug for treatment and control of schistosomiasis killed worms in 
vivo within 24 h (Shaw, 1990).  
Although mefloquine kills schistosomes in our in vitro study without the addition of hemin, a 
heme dependency study revealed that in the presence of hemin the antischistosomal 
activities of mefloquine are further pronounced. The latter result is in line with the mechanism 
of action of mefloquine in malaria parasites. It was shown that in Plasmodia spp. mefloquine 
and also other 4- aminoquinoline antimalarial drugs interfere with the hemoglobin pathway by 
inhibiting the essential formation of toxic hem into the untoxic hemozoin pigment  
(Sweeney, 1981, Correa Soares et al., 2009). This detoxification process was also shown for 
S. mansoni to be the main heme degradation pathway and it was demonstrated, that the 
antimalarial quinoline methanols interfere with the hemozoin formation of S. mansoni, which 
is suggested to represent the mechanism of schistosomicidal action of these compounds. 
Interestingly, the hemozoin content in female worms was more impaired after treatment with 
these drugs (Gönnert and Andrews, 1977). Overall, these studies confirm our results of a 
heme- dependent mechanism of mefloquine in schistosomes. However, in contrast to the 
antimalarial drug artemether, which only possess antischistosomal activities in vitro in the 
presence of hemin (Xiao et al., 2001), mefloquine seems to display its schistosomicidal 
activities with at least one other mechanism.  
SEM studies, a common technique to document efficacy of antihelminthic drugs  
(Neves et al., 2001), confirmed the schistosomicidal action of mefloquine and the observed 
difference in the onset of action between in vitro and in vivo studies. Mefloquine induces 
progressive and time-dependent alterations on the tegument of S. mansoni NTS and adult 
worms with extensive tegumental damages including blebbing, shrinking and sloughing. 
Severe damages were observed in particular following in vitro incubation and on the 
tegument of female worms. The observed discrepancy between in vitro and in vivo studies 
might be due to absorption and distribution effects of the drug in the mouse organism 
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resulting in lower drug concentrations at the target organs in vivo. Our observation that the 
tegument of females was more affected by mefloquine is in line with the results of the in vivo 
study of Keiser and colleagues, where mefloquine reached higher female worm burden 
reductions compared to total worm burden reductions (Keiser et al., 2009). In addition, this 
result is suitable to the findings of the above described hemozoin study, since female  
S. mansoni were found to be more affected after antimalarial drug treatment  
(Correa Soares et al., 2009). In contrast, praziquantel provokes more extensive tegumental 
damages to the male worms (Shaw and Erasmus, 1983).  
In addition to our result, an in vitro study (Holtfreter et al., 2011) as well as an in vivo stage 
specific susceptibility study showed, that mefloquine is effective against all parasite stages of 
S. mansoni and S. japonicum (Keiser et al., 2009). In contrast, praziquantel is only active 
against the adult blood flukes and has a lack of efficacy against juvenile schistosomes  
(Cioli and Pica-Mattoccia, 2003, Pica-Mattoccia and Cioli, 2004). 
 
Taken together the following findings let us conclude that both drugs may differ in their 
modes of action and act on different target proteins: First, mefloquine and praziquantel have 
sex-specific differences and induce different types of morphological changes and tegumental 
alterations on S. mansoni. Second, mefloquine and praziquantel have different spectra of 
activity. Third, mefloquine seems to have a hemin dependent and hemin independent 
pathway in schistosomes, since not only heme feeding adults, but also the non 
hematophagous schistosomula are susceptible to that drug. 
 
The mode of action of mefloquine is thus different from praziquantel and is not restricted to 
the presence of heme. In order to discover drug targets for mefloquine in schistosomes, we 
have performed affinity chromatography with schistosomula crude extracts, and have 
identified a S. mansoni enolase (EC 4.2.1.11; Q27877), a glycolytic enzyme, as a major 
mefloquine- binding protein in schistosomula. Moreover, results obtained with IMC suggest 
that mefloquine interferes with glycolysis thus causing rapid death of the worms. For  
S. japonicum it was shown that the enolase gene was significantly higher expressed in the 
schistosomula stage as well as during development phase into adult worms. This finding that 
enolase is critical for the rapid growth, migration and survival of the worms (Yang et al., 
2010). This function of the enzyme may confirm our hypothesis that mefloquine exert its 
antischistosomal activity (at least partly) via enolase, since mefloquine disturbs an important 
and life-supporting regulating mechanisms of the parasite. Already in 1950 it was shown that 
glycolysis is essential for the survival of S. mansoni, but the respiratory metabolism is not 
(Bueding, 1950). In the same study it was shown that also funadin (antimonial) and 
naphthoquinone (structural similarities to mefloquine) inhibit glycolysis in schistosomes and 
showed chemotherapeutic effects in experimental schistosomiasis. Further investigations 
with adult schistosomes, sex-specific interactions (female schistosomes tend have a lower 
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rate of glycolysis than males, because they contain less glycogen as males), and drug 
screening studies with funadin, naphthoquinone, fluoride (selective effect on enolase) and 
other known inhibitors of glycolysis should be undertaken to deepen our understanding on 
glycolysis as potential target pathway for drugs. 
Since mefloquine and naphthoquinone have structural similarities, another approach might 
be to determine which structure is required for antischistosomal activity.  
 
We already demonstrated in a structure-activity study that the optical isomers and the 
racemic forms of the chiral drug mefloquine are characterized by only moderate 
stereoselectivity, in particular in vivo since prominent total and female worm burden 
reductions were observed with all derivates in the S. mansoni mouse model. The role of 
stereochemistry in the pharmacokinetics, efficacy and toxicity of drugs is very important for 
discovery and development of drugs today (Brocks and Jamali, 1995, Brocks and Mehvar, 
2003). However, we showed that none of the derivatives tested offers a therapeutic 
advantage over mefloquine. Indeed, the highest in vivo antischistosomal activities were 
observed with the erythro-racemate, the marketed form of the drug mefloquine. Furthermore, 
the (+) and (-) form of the erythro isomers showed the same overall activity in the S. mansoni 
mouse model and in vitro. It was hypothesized that (+) mefloquine might cause less side 
effects in the treatment of malaria, but interestingly a recent Phase I study has shown similar 
safety and tolerability profiles for the (+)- erythro isomer and the racemate 
(http://www.sosei.com/pdf/press_en_20100106_265.pdf). Therefore, since no advantages in 
the pharmacodynamics affect and in the safety profile of the (+) - erythro isomer were seen, 
a separation of the enantiomers is not needed from a therapeutical point of view. These facts 
facilitate the potential clinical use of mefloquine against schistosomiasis, since further studies 
can be undertaken with the marketed drug mefloquine. 
 
Our combination chemotherapy studies with mefloquine plus praziquantel against S. 
mansoni revealed synergistic effects in vitro and in the mouse model. Hence, the 
combination yields a result which is not independently obtainable by each drug alone. This 
can occur when drugs do not inhibit each other in pharmacokinetics or pharmacodynamics 
and act on different targets (ref). In our case this suggests that mefloquine has a different 
mode of action than praziquantel, which would also confirm our previous hypothesis 
described above. Both drugs, however, are only able to display their entire mechanism of 
action when mefloquine is administered 24 h prior to praziquantel, since the synergistic 
behavior of the combination in the mouse model was observed when both drugs were given 
simultaneously or when praziquantel treatment followed mefloquine. On the other hand only 
moderate worm burden reductions were achieved when praziquantel was administered prior 
to mefloquine.  
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Our previous findings that mefloquine disturbs the glycolytic pathway in schistosomes and 
the mode of action of praziquantel may explain the synergism between mefloquine and 
praziquantel. By giving mefloquine prior to praziquantel, the energy yield due to glycolysis is 
lowered and thus ATP depleted (Pelicano et al., 2006, Lithaw, 2009). If in a next step 
praziquantel is added, praziquantel exerts its mode of action and causes muscle contraction 
by opening of the calcium channels. Furthermore, due to the action of praziquantel against 
the tegument of the parasites, changes in permeability of tegumental membrane can be 
observed (Mehlhorn, 2001). Therefore parasites loose glucose and ATP pools of the 
schistosomes are further depleted until a point of no return, even with drug 
dosages/concentrations that are not effective if administered alone. These mechanisms can 
proceed in parts, when drugs are given simultaneously. On the other hand, if praziquantel is 
given first, an increase in tension and a disrupted tegument would decrease the uptake of 
mefloquine by schistosomes, resulting in lower activities of the drug combination (Andrews, 
1985).  
 
8.3. Antischistosomal drug discovery and methological issues 
 
Throughout the entire framework of my studies I evaluated in vitro drug effects against S. 
mansoni by manual microscopic reading, since this screening method is the current “gold 
standard” to assess the in vitro antischistosomal properties of test drugs (Keiser, 2010, 
Ramirez et al., 2007). Although the use of microscopy is easy to handle and accomplishable 
in every laboratory, microscopic reading is subjective and time extensive. Therefore, to 
improve antischistosomal drug screening, we have assessed a new technique, namely 
isothermal microcalorimetry (IMC), to examine drug activities against adult S. mansoni, and 
NTS. In general IMC measures the heat- flow of biological processes (endo- or exothermic 
reactions) over time and has already been applied for various studies of food deterioration, 
drug shelf life or the effects of antimicrobial agents.  
 
Our studies on in vitro effects of well-described antischistosomal drugs (praziquantel, 
oxamniquine and artesunate), and of the optical isomers and racemates of mefloquine 
against S. mansoni showed a good correlation between assessment by microscopy and IMC. 
Additionally, we found two key advantages for IMC. First, IMC allows identifying drug effects 
that were not visible by microscopic evaluation and second, IMC precisely determines the 
onset of action of the test drugs. On the other hand, microscopy allows investigating drug 
effects on morphology. Overall, we could show that IMC is a useful tool for antischistosomal 
drug discovery and helpful in the characterization of new hits. IMC is also applicable to 
monitor drug effects against a range of other helminths and their developmental stages 
where drug screening approaches are limited, for example, to study activities against 
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Fasciola hepatica or Echinostoma caproni (Kirchhofer et al., 2011). Results obtained with 
IMC, however, should be confirmed by phenotypic microscopic evaluation.  
There are also a few drawbacks for IMC. A big drawback is that the use of IMC is associated 
with high costs, since there are high initial costs for the microcalorimeter and other expenses 
for the appropriate material (e.g. glass ampoules). Therefore its use will be restricted to well-
equipped laboratories in high-income countries. Another drawback is that IMC does not allow 
high-throughput evaluation of drugs, since the IMC used in this study possess only 48 
individual measuring channels.  
 
Moreover, we also compared drug effects on the schistosomular (NTS) and adult stages, as 
the former developmental stage is increasingly being used in antischistosomal drug 
screening assays and by our laboratory (Abdulla et al., 2009, Keiser, 2010, Mansour and 
Bickle, Holtfreter et al., 2010). Our data support the use of NTS in in vitro antischistosomal 
drug assays, since we observe similar susceptibilities on NTS and adult schistosomes for 
praziquantel and mefloquine. Slight differences in the drug susceptibilities of the two 
developmental stages are, however, noted with oxamniquine and artesunate.  
 
8.4. Antimalarials against schistosomiasis: comments on new 
treatment options 
 
In our studies we have shown through several approaches that mefloquine and praziquantel 
have different spectra of activity and different mechanisms of action. Therefore a 
mefloquine/praziquantel combination chemotherapy might offer the following advantages: 
 
First, an improved treatment outcome compared to praziquantel monotherapy might occur. 
However, this has not been assessed in detail yet. Second, the threat of resistance is 
decreased. Third, less “re- infections” might occur. Usually, with praziquantel monotherapy, a 
follow up treatment after four to six weeks is necessary, because unaffected immature 
worms would mature to adult schistosomes (Gryseels et al., 2006). On the other hand 
mefloquine exhibit activities against juvenile schistosomes. The next step is to assess, if 
encouraging results obtained in the mouse model can be confirmed in patients. Proof of 
concept trials in schistosome infected children to evaluate the use of the 
mefloquine/praziquantel combination in cure, prophylaxis and safety have already been 
launched.  
 
Overall, the mouse is the best model organism for understanding human biology as well as 
disease mechanisms (genome is closely related to humans) and is the most commonly used 
mammalian host for in vivo drug discovery studies (including S. mansoni) (Keiser, 2010). 
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However, we do not know, whether synergistic effects observed with the combination 
mefloquine/praziquantel in the mouse model will also occur in patients, since not the entire 
complexity of human life, including pharmacokinetic and pharmacodynamic is reflected 
(Proetzel and Wiles, 2010) (http://genome.wellcome.ac.uk/doc_WTD023552.html) 
 
Another group of antimalarials with antischistosomal activities (mainly active against juvenile 
schistosomes) are the artemisinins. This was demonstrated in vitro, in vivo and in several 
clinical trials (Utzinger et al., 2010b, Borrmann et al., 2001, Utzinger et al., 2007, Utzinger et 
al., 2002). Therefore another possibility for a combination therapy against Schistosoma 
infection is the use mefloquine plus the artemisinin derivate artesunate. Indeed, a 
randomized, explatory open-label trail, which tested the efficacy and safety of a 
mefloquine/artesunate combination (artemisinin- based combination therapy (ACT)) in 
schistosome infected school children showed, that 11 out of 18 S. haematobium infected 
children were cured (Keiser et al., 2010). Praziquantel monotherapy achieved cure rates of 
88%. Egg reduction rates were for both treatment regimes > 95%. A handful of patients were 
concurrently infected with S. haematobium and S. mansoni. In this case, high cure rates 
were also achieved against S. mansoni. Drugs were administered in accordance with current 
malaria treatment schedule. The effect of a praziquantel/mefloquine/artesunate combination, 
which will also be assessed in the framework of the above mentioned proof of concept study, 
will therefore be interesting to note. 
 
However, the use of antimalarials for the treatment and control of schistosomiasis have to be 
regarded with extreme caution because of the concern of antimalarial resistance. That is also 
one reason why the artemisinins, the most powerful antimalarials discovered so far, are used 
in combination therapy for malaria treatment. Therefore the ACTs must be reserved for 
prevention and control of malaria (Utzinger et al., 2010b). However, since the ACTs are 
already used against malaria in sub Saharan Africa where malaria and schistosomiasis co 
exist, a potential ancillary effect against schistosomiasis might be obtained. One the one 
hand, people who will be treated with mefloquine plus artesunate would be cleared from 
malaria parasitemia and on the other hand schistosomiasis related morbidity would be 
reduced.  
 
8.5. Implications and suggestions for further research 
 
• To conduct structure activity relationship studies with structural derivates of 
mefloquine to elucidate which structure is required for activity and therefore to 
increase efficacy and decrease side effects. 
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• To conduct proof of concept trials with mefloquine/praziquantel combinations. 
 
• To investigate the antischistosomal properties of mefloquine, single and in 
combination, against S. haematobium, since S. haematobium is an important and 
neglected parasite. 
 
• To assess, whether mefloquine also interferes with glycolysis in adult schistosomes.  
 
• To search for non-toxic inhibitors of glycolysis in schistosomes, since we documented 
an interaction of mefloquine with glycolysis, an essential metabolic reaction in S. 
mansoni schistosomula. For example, by testing marked drugs against schistosomes, 
which interact with glycolysis in parasites, protozoa or bacteria as a kind of “piggy 
back” strategy. 
 
• Since liver infections often strongly influence kinetics and metabolism, the 
pharmacokinetic of mefloquine should be studied in infected hosts. It will be 
interesting to note, whether t1/2, cmax and AUC will be altered in infected mice.  
 
 
8.6. Conclusion 
 
In conclusion, my work has confirmed that mefloquine has excellent antischistosomal 
properties in vitro and in vivo. Furthermore, mefloquine might be an interesting partner drug 
in combination chemotherapy against schistosomiasis. We demonstrated that IMC is a useful 
tool for antischistosomal drug discovery and should be therefore be assessed also for 
studying drug effects against other helminths. In addition, our data support the use of NTS in 
in vitro antischistosomal drug assays.  
However, although chemotherapy is the key factor to control and reduce morbidity due to 
schistosomiasis, and thus there is a pressing need to develop new antischistosomal drugs, 
safe water supply and sanitation should also not be neglected  
(Utzinger et al., 2010a, Sarvel et al., 2011). 
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9. Appendix: Impressions from the laboratory 
 
 
 
 
 
 
 
 
 
Entrance into the  
„wormy world“ Chemicals 
Tank with host snails 
of S. mansoni 
Biomphalaria 
glabrata 
NTS pellet 
In vivo work 
S. mansoni infec- 
ted mouse (7 w.) 
S. mansoni couple  
in liver 
Worms in mesenteric veins 
Schistosomes in 
culture media 
Light microscope 
picture 
Preperation for in vitro assays 
In vitro assay (adult worms) 
IMC: manual 
drug injection 
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